Instruction for use: Berlinsulin H 30/70 pen

ATX Code A10AB01 Human insulin

Active substance Insulin biphasic [human semisynthetic]

Pharmacological group

Insulins

Nosological classification (ICD-10)Z31.1 Artificial insemination

E10 Insulin-dependent diabetes mellitus

Decompensation of carbohydrate metabolism, Diabetes mellitus, Diabetes insulin sugar, Diabetes mellitus type 1, Diabetic ketoacidosis, Insulin-dependent diabetes, Insulin-dependent diabetes mellitus, Coma hyperosmolar non-ketoacidotic, Labile form of diabetes mellitus, Violation of carbohydrate metabolism, Type 1 diabetes mellitus, Type I diabetes mellitus, Insulin-dependent diabetes mellitus, Type 1 diabetes mellitus

E11 Non-insulin-dependent diabetes mellitus

Acetonuric diabetes, Decompensation of carbohydrate metabolism, Diabetes insulin-independent sugar, Diabetes sugar type 2, Type 2 Diabetes, Non-insulin-dependent diabetes, Non-insulin dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Insulin resistance, Insulin resistant diabetes mellitus, Coma lactobacillus diabetic, Violation of carbohydrate metabolism, Type 2 diabetes mellitus, Diabetes mellitus type II, Diabetes mellitus in adulthood, Diabetes mellitus in old age, Diabetes insulin-independent, Diabetes mellitus type 2, Sugar insulin-independent diabetes type II

Composition and form of release

1 ml of the suspension for injection contains insulin of human 100 ED (30% soluble normal insulin and 70% crystalline suspension with protamine) and protamine sulfate 0.24 mg (corresponding to 0.189 mg protamine base); In cartridges of 1.5 ml, in a box of 5 pcs.

pharmachologic effect

Pharmacological action - hypoglycemic.

Interacts with a specific receptor of the plasma membrane and penetrates into the cell, which activates protein phosphorylation, stimulates glycogen synthase, pyruvate dehydrogenase, hexokinase, inhibits fat lipase lipoprotein lipase. In combination with a specific receptor facilitates the penetration of glucose into cells, increases the absorption of glucose by tissues and facilitates its conversion into glycogen. Increases the glycogen reserve in muscles, stimulates the synthesis of peptides.

Clinical Pharmacology

It is a medication with an average duration of action. The maximum effect develops after 1-8 hours and lasts 14-15 hours.

Indications

All forms of type I and type II diabetes mellitus.

Contraindications

Hypersensitivity (relative), hypoglycemia.

Side effects

Hypoglycemia.

Dosing and Administration

Usually the daily dose is divided into two injections in a ratio of 2: 1 (2/3 in the morning and 1/3 in the evening) and injected sc for 30-45 minutes before breakfast and dinner. With each injection, the injection site is changed.

storage Conditions

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.